To expand the scope of capmatinib in NSCLC with MET exon 14 skipping, a phase II trial (NCT04926831) is recruiting patients to evaluate the possibility of using capmatinib in neoadjuvant and adjuvant treatment. This evidence concerns the gene MET and non-small cell lung carcinoma.